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Abstract
Myocardial infarction (MI) may produce significant inflammatory changes and adverse ven-
tricular remodeling leading to heart failure and premature death. Pharmacologic, stem cell
transplantation, and exercise have not halted the inexorable rise in the prevalence and
great economic costs of heart failure despite extensive investigations of such treatments.
New therapeutic modalities are needed.Whole Body Periodic Acceleration (pGz) is a non-
invasive technology that increases pulsatile shear stress to the endothelium thereby pro-
ducing several beneficial cardiovascular effects as demonstrated in animal models, normal
humans and patients with heart disease. pGz upregulates endothelial derived nitric oxide
synthase (eNOS) and its phosphorylation (p-eNOS) to improve myocardial function in mod-
els of myocardial stunning and preconditioning. Here we test whether pGz applied chroni-
cally after focal myocardial infarction in rats improves functional outcomes from MI. Focal
MI was produced by left coronary artery ligation. One day after ligation animals were ran-
domized to receive daily treatments of pGz for four weeks (MI-pGz) or serve as controls
(MI-CONT), with an additional group as non-infarction controls (Sham). Echocardiograms
and invasive pressure volume loop analysis were carried out. Infarct transmurality, myocar-
dial fibrosis, and markers of inflammatory and anti-inflammatory cytokines were determined
along with protein analysis of eNOS, p-eNOS and inducible nitric oxide synthase (iNOS).At
four weeks, survival was 80% in MI-pGz vs 50% in MI-CONT (p< 0.01). Ejection fraction
and fractional shortening and invasive pressure volume relation indices of afterload and
contractility were significantly better in MI-pGz. The latter where associated with decreased
infarct transmurality and decreased fibrosis along with increased eNOS, p-eNOS. Addition-
ally, MI-pGz had significantly lower levels of iNOS, inflammatory cytokines (IL-6, TNF-α),
and higher level of anti-inflammatory cytokine (IL-10). pGz improved survival and contractile
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Introduction
Myocardial Infarction (MI) and its associated functional derangements may lead to heart fail-
ure that affects 2–3% of the population in industrialized countries with a marked rise in those
aged>65yr. A combined estimate of ~ 20 million people suffer from heart failure in Europe
and the US and its prevalence is increasing. In the US alone direct medical costs approximate
$25 billion dollars per year and expected to triple by 2030 [1–4].
Attempts to ameliorate myocardial dysfunction after MI, using pharmacologic, stem cell
transplantation, and exercise have been widely explored in experimental and in clinical trials.
The search for simple inexpensive therapeutic interventions continues. Whole Body Periodic
Acceleration (pGz) is the repetitive, sinusoidal head-foot motion of the body provided by a mo-
tion platform. As the body accelerates and decelerates, low amplitude pulses are added to the
circulation as a function of platform frequency thereby increasing pulsatile shear stress to the
endothelium [5–8, 9]. pGz through its increase of pulsatile shear stress upregulates eNOS and
increases its phosphorylation p-eNOS (Ser 1177) [10] eNOS phosphorylation after pGz is respon-
sible for shear stress dependent vasodilatation and subsequent increase nitric oxide (eNO) re-
lease into the circulation [9, 11–13]. pGz applied in a swine model of myocardial stunning
induced by whole body ischemia reperfusion injury, acutely improves myocardial function due
to increase eNO as well as other cardioprotective mediators [6, 8, 10, 14]. The purpose of this
investigation was to test whether pGz applied chronically after focal myocardial infarction in
rats would improve functional outcomes fromMI.
Materials and Methods
Animals and Experimental Design
The experimental protocol No. 13-08-A-03 was approved by the Mount Sinai Medical Center
Animal Care and Use Committee and conforms to the Guide for the Care and Use of Laborato-
ry Animals published by the National Institutes of Health [NIH Publication No. 85-23, revised
1996]. Adult male Sprague-Dawley rats (300–350 g) were randomly assigned to (n = 60): 1)
pGz started 24 hr after MI, 1 hr per day 5 days per week for four weeks (MI-pGz) (n = 20); 2) A
control group (MI-CONT) animals were placed on the pGz platform starting at 24 hr after MI
but the platform was not actuated (n = 20); 3) Sham group, animals where anesthetized but no
MI was induced (Sham) (n = 10) (Fig. 1).
pGz Protocol
After experimental MI was induced by permanent ligation of the left coronary artery, the ani-
mals recovered for 24 hr. Awake animals were placed in a restraint for 1hr/day 5 days per week
for four weeks. Optimal pGz frequency of 360 cpm and peak acceleration amplitude of
Gz ± 2.9 m/sec2 in rats for increased release of eNO was utilized [10, 13]. pGz was administered
at the same time of the day for the various study groups. Animals who did not receive pGz
were placed in the same restraint for the same number of days as the experimental groups.
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Myocardial Infarction Model
Animals were anesthetized with Ketamine/Xylazine (80/10 mg/kg IM) intubated and ventilated
with O2 using a small-animal ventilator (Kent Scientific Corporation, Torrington, CT). Body
temperature was maintained at 37.5 ± 0.5°C with a heated operating platform. Cardiac electri-
cal activity was monitored continuously with 3 lead electrocardiogram. The tail vein was cathe-
terized for intravenous fluids and drug administration. Left thoracotomy was performed and a
permanent ligature placed around left anterior coronary artery at the mid-level. The thorax
was closed in layers with silk sutures. Animals were extubated and recovered in their cages
maintaining a thermo-neutral environment and received analgesia [Buprenex (buprenorphine)
0.1 mg/kg] immediately after surgery and every 6 to 12 hr. based on pain assessment. Animals
are monitored hourly or until upright and ambulating. Once ambulating animals are assessed
for post procedural pain every 4 hr. for the initial 48 hr., thereafter once per day until comple-
tion of the protocol. A modified score sheet system based on post procedural pain assessment
of behavior, physiological stress signs and respirations is used to tabulate assessments (S1
Table) [15–17].
Echocardiogram and Invasive Hemodynamic Measurements
Echocardiograms where performed post MI at 1, 3,and 4 weeks of pGz or Control using an HP
Sonos 2000 ultrasound imaging system (Hewlett-Packard, Andover, MA USA) with a 7.5 mHz
transthoracic transducer. 2D/M-Mode techniques were applied to assess functional changes.
Echocardiograms were performed in long- and short-axis following myocardial infarction in
close-chest sedated rats. The chest was shaved and covered with ultra sound gel in order to pro-
vide air-free insonation. The left ventricle (LV) was visualized by middle long and short axis
images. Middle long and short axis views were taken from the right ventricular side in order to
Fig 1. Myocardial Infarction Protocol Schematic. Permanent ligation of left coronary artery without reperfusion was done. pGz or Control were begun
24 hr after MI, and continued for four weeks. Post-MI echocardiograms (Echo) were done immediately post MI, at 1,3,4 weeks. Invasive Pressure Volume
Loops were collected at end of study.
doi:10.1371/journal.pone.0121069.g001
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depict the left ventricle at a lower sector-angle. By reducing insonation angle without reducing
spatial resolution, the technique provided images with a 76 frame rate. Three cardiac cycles
were acquired and averaged by software. The correct tracking of border zones was visually con-
trolled and manually corrected. Ejection time was defined by Doppler-registered aortic valve
opening and closure. Conventional measurements (LV diameters, anterior wall (AW) and pos-
terior wall (PW) thickness and thickening) were obtained from grayscale M-mode tracings. LV
end-systolic and end-diastolic volumes and LV ejection fraction (LVEF) were measured by
Simpson’s method from two-dimensional parasternal long- and short-axis views [18–20].
After four weeks of pGz or Control the animals where anesthetized and catheterization was
performed with a Millar Catheter SPR-869 (Millar Instruments, Houston TX, USA). The con-
ductance catheter was calibrated by a cuvette calibration method using an actual blood sample
in cuvette between 50 and 300 μl. In vivo the conductance signal was calibrated using hyper-
tonic saline. An intravenous bolus of 50 μl of 20% saline was used to perform calibration. In
order to decrease preload, a small abdominal incision was performed to localize and perform
inferior vena cava (IVC) occlusions. PVL where continuously recorded at baseline, after saline
infusion, and during and after IVC occlusions. Recording and calculations were performed
using data acquisition software (LabChart7Pro, ADInstruments, Colorado Springs, CO).
Sham Surgery
Sham protocol was identical to MI experiments with the exception of coronary artery ligation.
At the completion of the sham surgery, animals were recovered and allowed to remain in their
cage with free access to chow and water for the remainder of their study time period.
Animals which met pre-established humane endpoints for euthanasia or completed the ex-
perimental protocol were euthanized by a dose of Ketamine 90mg/kg and Xylazine 25mg/kg,
followed by pentobarbital 100mg/kg IP, until absence of corneal and pedal reflex, and no elec-
trical activity on ECG, and decapitation via guillotine, a method approved by the American
Veterinary Medical Association Guidelines on Euthanasia. Perfusion and or organ harvesting
was performed as per protocol [21–24].
Detection and Assessment of Infarcted Area, Transmurality and Fibrosis
Validation of coronary occlusion was performed by our laboratory according to the procedure
previously described [25]. In a separate cohort of animals (n = 10) infarct size was determined
after 24 hr. of coronary occlusion to determine infarct size. At the end of the study (four weeks
after ligation) and after all hemodynamic measurements, the aorta was clamped and the hearts
were perfused with 10mL of saline through a cannula in the ascending aorta to wash out the
blood from the myocardium [26]. After saline perfusion, Evans Blue (EB) was injected into the
ascending aorta to separate the non-at-risk area from the risk area. The hearts were cut out and
cut in 3, 3mm segments from apex to base parallel to the atrioventricular groove. The segments
were incubated for 30 minutes in 2,3,5-triphenyltetrazolium chloride (TTC) at 37°C in the
dark. The segments were fixed between two glass sheets and non-at-risk area, the area-at-risk
and the necrotic area were determined by planimetry [27]. The basal side of the segments was
measured to better distinguish between myocardium stained by EB and TTC. Segments for
comparison were chosen on the basis of reproducibility of area-at-risk to perfused myocardium
ratio between animals. Images of the segments were taken with a digital camera set to 60 x
magnifications through a dissecting microscope (Olympus, Center Valley, PA). Viable myocar-
dium (TTC red stained) and infarcted (TTC unstained) areas non-at-risk area (EB–blue
stained) were measured using a computer program (Adobe Photoshop, Adobe Systems Incor-
porated, San Jose, CA). The percentage share of each the preceding areas was calculated.
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Area at risk measured by the Evans Blue (EB) perfusion-staining and expressed as percent
of whole heart. Necrosis was measured by TTC staining and expressed as percent of each myo-
cardial segment. To determine transmurality of the infarct scanned images of the segments
were geometrically divided into a 6-sector model using the anterior and inferior insertion of
the right ventricle to the left ventricle as markers [28]. Apical, middle and basal necrosis was
defined. The sectors were divided into the following groups on the background of the distribu-
tion of necrotic myocardium: transmural necrotic (necrosis>50%), subendocardial necrotic
(1–50% necrosis) and viable (necrosis = 0). The combination of the two latter groups is referred
to as predominantly viable (0–50%).
Transmural necrotic sectors display thinning of the myocardial circumferential areas of left
ventricular wall. Transmurality of the infarct was defined as the sum of the epicardial and en-
docardial infarct circumference divided by the sum of the total LV epicardial and endocardial
circumferences using computer-based planimetry [29]. Fibrosis was measured by Masson's
Trichrome (MT) staining and expressed as percent of left ventricle in a segment. Hearts were
washed three times in PBS at 4°C. Hearts were then cut into three transverse segments. Each
segment was fixed in 10% para-formaldehyde and embedded in paraffin. The middle trans-
verse segment was sectioned and stained with MT for both wall thickness (epi-to-endocardial
distance) and fibrosis (blue stained collagen fibers) measurements. The mean left ventricle
(LV) wall thickness, fibrosis and total LV area were measured from three equidistant points.
Tissue Preparation for detection of eNOS, p-eNOS, iNOS TNF-α, IL-6
and IL-10
To assess the effects of pGz on eNOS, p-eNOS and iNOS and inflammatory TNF-α, IL-6 and
anti-inflammatory cytokine IL-10 protein levels were determined. Samples of the left ventricle
were removed and immediately frozen in liquid nitrogen for Western Blot and cytokine protein
chemiluminescent analysis. Care was taken to consistently harvest the same region of the left
ventricle from all animals. Sections of the left ventricular myocardium were individually
minced and homogenized at 4° C followed by one step total protein extraction with an Extrac-
tion Buffer System (Invitrogen Corporation, Carlsbad, CA) according to the manufacturer’s
protocol. Homogenates were centrifuged at 4°C for 20 minutes at 12,000 rpm. The supernatant
was decanted and assayed for total protein content. The extracted total cardiac tissue protein
was measured by the BCA Protein Assay (Thermo Fisher Scientific, Waltham, MA) on a Spec-
traMax Plate Reader (Molecular Devices, Sunnyvale, CA). Individual proteins were then ana-
lyzed by Western Blot. Equal amounts of total protein were separated on 4–12% NuPAGE
Novex Bis-Tris SDS-PAGE Gels (Invitrogen Corporation, Carlsbad, CA) and transferred to
Immobilon-FL PVDF membrane (Millipore Corporation, Billlerica, MA). The PVDF mem-
brane was treated with a blocking agent (GE Healthcare Bio-Sciences Corporation, Piscataway,
NJ) and probed with primary, fluorescein-linked secondary antibodies as well as anti-fluoresce-
in alkaline phosphatase conjugate. Primary antibodies to eNOS, p-eNOS(Ser1177), iNOS, and
GADPH (Glyceraldehyde-3-phosphate dehydrogenase) as an individual protein loading con-
trol (Santa Cruz Biotechnology, Inc. Santa Cruz, CA.) were employed. TNF-α, IL-6, IL-10
where determined using Rat Cytokine Kit (R&D Systems Inc., Minneapolis, MN). Equal
amounts of protein 400 μg were used for analysis. Cytokine levels where normalized to Sham
samples. Blots were visualized by Enhanced Chemifluorescence (ECF) (GE Healthcare Bio-Sci-
ences Corporation, Piscataway, NJ) on Storm 860 Imaging System (GE Healthcare Bio-Sci-
ences Corporation, Piscataway, NJ). The Storm 860 Imaging System exhibits a linear response
to fluorescent signal intensities and protein levels were quantified using ImageQuant software
(GE Healthcare Bio-Sciences Corporation, Piscataway, NJ).
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Data Analysis
Primary outcomes are survival and myocardial infarct size. Secondary outcomes are myocardi-
al fibrosis, hemodynamics and protein expression. Myocardial contractility measurements
were analyzed using a two-way analysis of variance with repeated measures. When appropriate,
post hoc Fisher’s least significant difference test was carried out. Myocardial protein analysis
parameters were subjected to analysis of variance with a Fisher’s least significant difference test
used post hoc. Statistical significance was established at p<0.05. Sample size was calculated
using Statistica (StatSoft, Tulsa, OK) based on power analysis with α = 0.05 and power 0.80. All
data are expressed as Mean ± SD.
Results
Survival and Myocardial Infarct Size and Myocardial Fibrosis
All animals survived myocardial infarction without reperfusion at 24 hr. At 1 week post MI,
70% of the MI-CONT and 90%MI-pGz animals survived (p< 0.01). Four weeks after MI, 80%
of the pGz treated animals survived and 50% of the MI-CONT (p< 0.001) (Fig. 2).
Fig 2. pGz Improves Survival After Myocardial Infarction. Kaplan-Meir Survival Curves. Survival during the four weeks after myocardial infarction in MI-
pGz and MI-CONT groups. † p< 0.01.
doi:10.1371/journal.pone.0121069.g002
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Infarct size prior to randomization was 38±4%. Treatment with pGz for four weeks de-
creased transmurality of the infarct from 60± 5% for MI-CONT to 48±4% for MI-pGz (p<
0.01). The ratio of left ventricular wall thickness to the MI thickness was significantly smaller
in MI-CONT 0.9±0.5 compared to 3.1 ± 0.7 for MI-pGz (p< 0.01), additionally the amount of
left ventricular collagen was 35±4% in MI-CONT compared to 22±4% in pGz treated animals
(p< 0.01)(Fig. 3).
Hemodynamics and Myocardial Performance
Ejection fraction and Fractional shortening significantly decreased at 1, 3, and four weeks after
MI in both MI-CONT and MI-pGz compared to the immediate post MI time period. Over the
four week post MI period, EF decreased an average of 35% from immediate post MI values in
MI-pGz, while in MI-CONT the average decrease was 53%. Similarly FS, decreased on average
46% in MI-pGz, and 56% in MI-CONT (p< 0.01) (Fig. 4).
As expected and in agreement with other studies, MI significantly decreased invasive mea-
sures of afterload, preload, integrated myocardial performance, and contractility [30, 31]. Four
weeks of pGz significantly improved left ventricular end systolic pressure (LVESP) and invasive
contractility measures, including; dp/dt, end systolic and end diastolic pressure volume relation
(ESPVR, EDPVR), and significantly improved LVEDP, compared to MI-CONT. (Table 1,
Fig. 5).
Protein expression of eNOS, p-eNOS, iNOS, TNF-α, IL-6 and IL-10
Compared to sham animals four weeks after myocardial infarction, there was a significant de-
crease in left ventricular protein content of eNOS (66%), p-eNOS(55%), and a significant in-
crease in iNOS (100%). pGz after MI significantly increased eNOS (78%), p-eNOS (56%) and
abrogated the increase in iNOS to only 20% compared with MI-CONT(Fig. 6).
pGz after MI decreased left ventricular protein content of IL-6 and TNF-α to 33% and 25%
respectively of MI-CONT (p< 0.01). pGz also significantly increased the anti-inflammatory
signaling cytokine IL-10, 100% of MI-CONT (p< 0.01). Additionally, the ratio of IL-10/ TNF-
α was also significantly increased 1.1± 0.05 vs. 0.4±0.05 in MI-pGz vs. MI-CONT (p< 0.01)
(Fig. 6.).
Discussion
Our study assessed the beneficial functional effects of treatment with pGz after experimental
MI in rats. pGz administered one hour daily significantly improved survival and myocardial
function. It decreased myocardial fibrosis and transmurality of the infarct, associated with in-
creased eNOS, p-eNOS, and IL-10 along with decreased expression of TNF-α, IL-6 and iNOS.
pGz Improves Survival and Hemodynamics
pGz improved survival and contractile performance in this post MI model of heart failure. pGz
has been shown to increase myocardial p-eNOS and NO and induce genomic up regulation of
eNOS. The present study shows that daily pGz after MI significantly increases eNOS and p-
eNOS, while significantly decreasing iNOS expression. Additionally pGz has also been shown
to increase myocardial nNOS [10, 13, 32, 33]. The role of NO in cardioprotection and as a ther-
apeutic modality in myocardial repair and remodeling, has been extensively reviewed by other
investigators with both eNOS and nNOS playing a significant role in lessening injury, reducing
apoptosis, decreasing myocardial fibrosis and ameliorating injury mediated by both reactive
oxygen (ROS) and nitrogen oxide species (RNS) [34, 35]. Pharmacologic enhancement of
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Fig 3. pGz Reduced Infarct Size, Transmurality and Fibrosis. A. The ratio of left ventricular wall to myocardial infarct length in MI-CONT and MI-pGz, with
representative microscopic findings. †p< 0.01 MI-CONT vs. MI-pGz. B. Left Ventricular Collagen as a % of the left ventricle in MI-CONT and MI-pGz, with
representative microscopic findings. Blue staining denotes fibrosis †p< 0.01 MI-CONT vs. MI-pGz.
doi:10.1371/journal.pone.0121069.g003
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eNOS and nNOS has also been shown to be cardioprotective after MI in mice [36] and enhanc-
ing mesenchymal cell therapy in swine [37]. The role of iNOS in myocardial repair and remod-
eling is less clear and controversial; with studies suggesting that increased NO production thru
overexpression of iNOS contributes to detrimental cardiac remodeling in heart failure, [38–40]
and lack of iNOS improving cardiac reserve post MI [41]. In contrast others showed a protec-
tive role for iNOS in LV remodeling in a cardiomyopathy hamster heart model [42]. Recently,
potentiation of NO signaling through inhibition of phosphodiesterase 5 (PDE5) has shown ef-
fectiveness in preventing cardiac hypertrophy and heart failure induced by pressure overload
in animal models as well as, promising for human heart failure, diabetic cardiomyopathy, and
pulmonary hypertension [43].
pGz Treatment Decreases Myocardial Fibrosis
Daily pGz treatment commencing 24 hr. after ischemia for four weeks improved the amount of
viable left ventricle as evidenced by a higher ratio of left ventricular wall thickness to myocardi-
al infarct thickness, and lower transmural extension of the infarct. Additionally, left ventricular
collagen content, a measure of myocardial fibrosis, was reduced by 37% in pGz treated animals.
The latter was associated with a decrease in pro-inflammatory cytokines, and increase in anti-
inflammatory signaling cytokine.
Cytokines and chemokines have been shown to be important signaling molecules for early
fibrosis [44–49]. In our model of MI, TNF-α and IL-6 measures of pro-inflammation were
Fig 4. Ejection Fraction and Fractional Shortening. A. Ejection Fraction (EF%) determined by echocardiogram immediately after MI (Post-MI) and at
1,3,4 weeks. * p< 0.01 MI-CONT and MI-pGz at 1,3,4 weeks vs. Post-MI. †p< 0.01 MI-CONT vs. MI-pGz. B. Fractional Shortening (FS%) determined by
echocardiogram immediately after MI(Post-MI) and at 1,3,4 weeks. * p< 0.01 MI-CONT and MI-pGz at 1,3,4 weeks vs. Post-MI. †p< 0.01 MI-CONT vs. MI-
pGz.
doi:10.1371/journal.pone.0121069.g004
Table 1. Invasive Hemodynamic Measures of Myocardial Function.
Sham MI-CONT MI-pGz
Heart Rate (bpm) 322(15) 348(20) 351(11)
Integrated Performance
EF(%) 67(1) 35(3.4)* 48(1.3)*†
SW (mmHgxμl) 9959(288) 8342(472)* 8478(380)*
Afterload
LVESP(mmHg) 149(3) 133(2.5) * 140(1.4)*†
Preload
LVEDP(mmHg) 9(1) 22(6)* 11(3)†
Contractility
dP/dtmax (mmHg/s) 13,593(228) 7,742(225)* 11,916(14) *†
ESPVR (mmHgxμl) 2.64 (0.19) 1.08(0.06)* 1.58(0.16) *†
EDPVR (mmHgxμl) 0.041(0.003) 0.083(0.004)* 0.063(0.011) *†
Invasive hemodynamic measures obtained from the analysis if the pressure volume relationship of
myocardial function at four weeks after myocardial infarction in Sham, MI-CONT and MI-pGz. Ejection
Fraction (EF%), Stroke work (SW), Left Ventricular End Systolic Pressure (LVESP), Left Ventricular End
Diastolic Pressure (LVEDP), End Systolic Pressure Volume Relationship (ESPVR), and End Diastolic
Pressure Volume Relationship (EDPVR).
* p< 0.01 MI-CONT and MI-pGz vs. Sham.
†p< 0.01 MI-CONT vs. MI-pGz.
doi:10.1371/journal.pone.0121069.t001
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reduced in pGz treated animals while IL-10 an anti -inflammatory signaling cytokine was in-
creased in pGz treated animals. Additionally, the balance of IL-10/ TNF- α in pGz treated ani-
mals was shifted to the more favorable anti-inflammatory ratio. Other investigators have also
shown that both exercise and statins may also shift this ratio [50, 51].
During myocardial ischemia, TNF- is released from macrophages, monocytes and mast
cells and after reperfusion TNF- is expressed and secreted in both cardiomyocytes and fibro-
blasts[52]. TNF- has an ambivalent role in MI depending on the receptor subtype that is acti-
vated. Cell signaling through TNFR1 exacerbates remodeling, hypertrophy and apoptosis in
heart failure, whereas TNFR2 has opposite effects [53].
Physical exercise decreases symptoms of coronary heart disease and is at the core of cardiac
rehabilitation [54, 55]. Exercise as a method ameliorating ventricular remodeling after MI has
been reported in various animal models including rats [50, 56], and humans [57, 58]. In rats
and pigs, we previously showed that a single hour of pGz induces upregulation and activation
of nNOS, eNOS and Akt and their respective phosphorylated proteins in the heart within 4 hr.
of exposure [8, 10]. In the current study, pGz after MI also increased eNOS protein expression
and phosphorylation.
Fig 5. Invasive Pressure Volume Relationship. Representative loops for the pressure volume relationship of the left ventricle four weeks after myocardial
infarction determined at baseline, and after reduction of preload via occlusion in Sham, MI-CONT and MI-pGz.
doi:10.1371/journal.pone.0121069.g005
Improved Ischemic Heart Function after pGz
PLOSONE | DOI:10.1371/journal.pone.0121069 March 25, 2015 11 / 18
Fig 6. pGz Increases eNOS Signaling and IL-10 Expression, whereas it Reduces iNOS, TNF-α and IL-6
Expression. A. Left ventricular protein content of endothelial derived nitric oxide synthase (eNOS) and
phosphorylated eNOS (p-eNOS) as well as inducible nitric oxide synthase (iNOS), for Sham, MI-CONT
and MI-pGz with representative immune blots for each group.* p< 0.01 MI-CONT and MI-pGz vs. Sham.
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Taken together our findings suggest that pGz post MI improves myocardial function, de-
creases inflammatory signaling, and modifies myocardial remodeling. It is plausible that these
changes are at least in part mediated via pGz-induced eNOS up regulation and modulation of
an inflammatory phenotype [35, 59–61].
How Does pGz Improve Survival and Contractile Performance
Several lines of evidence suggest that intracellular Ca2+ ([Ca2+]i) and Na
+ ([Na+]i) overload are
prime causes of myocardial injury and death during MI [62, 63]. An excessive increase of intra-
cellular Ca2+ causes mitochondrial dysfunction, reduces adenosine triphosphate (ATP) pro-
duction [64, 65], and activates Ca2+-dependent protease [66], all of which contribute to
impairment of the [Ca2+]i homeostasis. In addition, there is an important interplay between
[Na+]i and Ca
2+ handling, so that altered levels of [Na+]i and Na
+ transporters can have pro-
found effects on both contractile function and arrhythmogenesis [67, 68]. An increase in
[Na+]i activates the Na
+/Ca2+ exchanger in its reverse mode (Ca2+ in/Na+ out) which in turn
further elevates [Ca2+]i [69] whereas activation of Na
+/H+ exchanger induces acidification of
intracellular medium [70]. Thus, both [Ca]i and intracellular pH (pHi) in cardiac myocytes de-
pend strongly on [Na]i.
Using an in vitromodel of hypoxia and reoxygenation, we showed that pGz partially pre-
vented intracellular Ca2+ and Na+ overload and acidification of the intracellular medium dur-
ing hypoxia and reoxygenation [71]. This favorable effect regarding [Ca2+]i and [Na
+]i
concentrations by pGz may be explained on the basis of the multiple effects of NO as a cardio-
protective molecule [72–78]. These beneficial effects induced by pGz appear to be mediated by
increased production of NO since pretreatment with L-NAME, an inhibitor of nitric oxide
synthase blocks the pGz effect on intracellular [Ca2+], [Na+] and pH. Normalization of Ca2+
homeostasis in salvageable cardiomyocytes might also reduce cell death by necrosis and apo-
ptosis, decreasing the infarct size and reducing remodeling [79].
Limitations to the present study must be acknowledged. pGz increases serum prostaglan-
dins and adrenomedullin as well as myocardial nNOS, all which are cardioprotective [6, 8, 10,
14, 80–82]. The aforementioned were not analyzed in the current study. Additionally, we have
not directly measured NO levels in this model. Notwithstanding these limitations, our data
demonstrate that pGz applied after MI improves myocardial function, and favorably dimin-
ishes adverse myocardial remodeling after MI. These data are in agreement with early human
data, which showed that pGz after chronic MI, improved exercise capacity, and left ventricular
function and increased coronary flow reserve [83, 84].
Conclusions
The present study demonstrates that a non-pharmacologic, non-invasive intervention which
increases pulsatile shear stress to the vascular endothelium, can protect the heart after MI.
There are significant clinical applications to the pGz stimulus. In addition to being a precondi-
tioning stimulus, pGz may serve as a simple therapeutic modality to improve myocardial func-
tion after MI. pGz is particularly suited for individuals who cannot or will not exercise due to
physical or mental limitations. Since, pGz has been shown to be safe in healthy and diseased
†p< 0.01 MI-CONT vs. MI-pGz. B. Left ventricular protein content of the pro-inflammatory cytokines;
Interleukin 6 (IL-6) and Tumor necrosis factor alpha (TNF-α) and the anti-inflammatory cytokine; Interleukin
10 (IL-10) in Sham, MI-CONT and MI-pGz. * p< 0.01 MI-CONT and MI-pGz vs. Sham †p< 0.01 MI-CONT vs.
MI-pGz. C. Ratio of anti-inflammatory IL-10 to pro-inflammatory TNF-α cytokines. * p< 0.01 MI-CONT and
MI-pGz vs. Sham †p< 0.01 MI-CONT vs. MI-pGz.
doi:10.1371/journal.pone.0121069.g006
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human individuals and unlike exercise does not require subject cooperation, translation of its
use in humans post MI warrants clinical investigation [7, 84, 85].
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